TheraGenetics raises $6M for personalized medicine

TheraGenetics, a London biotechnology company developing personalized-medicine diagnostics, raised $6 million (£3 million) in a first funding round. The company is working on a diagnostic test designed to predict which patients are most likely to respond to antipsychotic drugs, including those for schizophrenia.

Swarraton Partners led the round, joined by Tudor Capital, IP Venture Fund, and IP Group. TheraGenetics was spun out of the King’s College Institute of Psychiatry.

Next Story:
Previous Story:

Tags:

Photo of David P. Hamilton

About the Author,

David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.

blog comments powered by Disqus